JM
John G Morikis (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Johnson & Johnson (JNJ). Across 1 priced purchase filing, the average 21-session return was +0.6% from execution and +0.2% from disclosure (delay-adjusted; derived). The largest single filing was $258K of JNJ (1,250 sh × $206.15, as filed), executed Nov 26 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+0.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+0.2%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
5d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$258K
shares × price, as filed
Last traded
Nov 26 2025
Filed Dec 1 2025
Median ADV $2.2B across their filed names
Open performance→Volume by month
Buys $258K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
JNJ
Johnson & Johnson
JNJ · 1 buy · 0 sells
1 filing
Recent filings
JNJPURCHASE
Johnson & Johnson
View filing →
$258K1,250 sh × $206.15
Exec Nov 26 2025
Filed Dec 1 2025 · 4:15 PM ET